Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280442 ↗Kurz gefasst
Leitlinie in der Zeitschrift PLOS ONE, 2023. Verfasst von Loïg Gaugain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Amaris Consulting, Montréal, Canada. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.
Abstract (Originalsprache)
Background and aims The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost-effectiveness of ATZ+BVA versus sorafenib in France based on an updated prices and considering French National real-world data, to confirm the initial recommendations from the Heath Technology Assessment submission published in 2021, and provide additional visibility to decision-makers reflecting current clinical practice.
Methods
A partition survival model was developed to project clinical outcomes, quality of life, and costs of patients with HCC treated with ATZ+BVA versus sorafenib over a lifetime horizon. Survival outcomes were extrapolated via parametric functions for both treatment strategies. Quality of life (EQ-5D-5L, French tariffs) were sourced from IMbrave150. The Guyot method was considered as a scenario analysis by integrating retrospective real-world data extracted from the French Health Insurance Database to refine long term survival extrapolations.
Results
In the reference case, ATZ+BVA was associated with 0.61 additional Quality Adjusted Life Years (QALYs) compared to sorafenib (1.95 vs 1.35), and an incremental cost of €92,704. The incremental cost-utility ratio (ICUR) was 152,974 €/QALY gained. Adjusting the survival curves with French external evidence led to a 14% ICUR reduction (131,163 €/QALY).
Conclusions
ATZ+BVA is a cost-effective strategy based on the range recently published for the value of a QALY in France and offers better chances of survival to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amaris Consulting, Montréal, Canada.
- Amaris Consulting, Paris, France.
- Amaris Consulting, London, United-Kingdom.
- Roche SAS, Boulogne-Billancourt, France.
- AP-HP, Liver Unit, Bobigny, France.
- Université Sorbonne Paris Nord, Bobigny, France.
ORCID-Profile: Hélène Cawston
Förderung
- Roche
Zitieren
APA
Gaugain, L., Cawston, H., Dubois de Gennes, C., Sanchez Alvares, J., Nahon, P., Mazaleyrat, B., & Le Dissez, C. (2023). Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLOS ONE. https://doi.org/10.1371/journal.pone.0280442
Vancouver
Gaugain L, Cawston H, Dubois de Gennes C, Sanchez Alvares J, Nahon P, Mazaleyrat B, et al. Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLOS ONE. 2023. doi:10.1371/journal.pone.0280442
BibTeX
@article{Gaugain2023,
author = {Gaugain, Loïg and Cawston, Hélène and Dubois de Gennes, Coline and Sanchez Alvares, Javier and Nahon, Pierre and Mazaleyrat, Benjamin and Le Dissez, Clément},
title = {Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280442}
}
EUVIMED